Special Issue "Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 July 2019
Assoc. Prof. Dr. Veysel Kayser
Various forms of antibody products, in particular full-size monoclonal antibodies (mAbs), have been dominating the biologics market as a result of their specificity and selectivity. They are also the mainstay for the development of next-generation biologics and biobetters for a number of disorders, including cancer. Currently, there are more than 70 approved antibody therapeutics on the market, but hundreds more are in clinical trials at various stages. Perhaps not surprisingly, a considerable number of these medications have been developed for the treatment of different types of cancers.
Because of the recent expirations of patent protections and changes in the regulatory framework around the world, biosimilars of widely used biologics, including mAbs, have slowly started to appear; nevertheless, we are yet to see a global impact of biosimilars. Notwithstanding the biosimilar development, a great deal of effort is being made to develop the next generation of mAbs. These comprise different forms of antibody products including, but not limited to, bispecific or multispecific mAbs, hyperglycosylated mAbs, antibody–drug-conjugates (ADC), single-domain antibodies (nanobodies), and antibody-based nanoparticles. The majority of these new developments transpired to address concerns of structural stability of antibodies, commonly observed formulation issues, strategies to prevent protein degradation especially due to aggregation or to enhance antibodies’ efficacy and specificity.
Trail-and-error methods still dominate the overall drug development and are commonly applied in different phases of the development of biologics, including antibody therapeutics. Rational drug development is only possible by the development of novel experimental and computational methods and by elucidating interactions at the molecular level. Most of the drug candidates comprising the next-generation biologics and antibody products would benefit from additional optimization. With the advance of experimental and computational methods, we can further optimize antibodies as never before.
In this Special Issue, we will collate a number of studies showcasing the current state of play as well as recent developments in mAb therapeutics and other antibody products used in cancer, their optimization using experimental and computational approaches, new developments in bi- and multi-specifics, ADC, nanobodies, and antibody-based nanoparticle arenas.
Assoc. Prof. Veysel Kayser
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Monoclonal Antibodies (mAbs)
- Antibody Medicines
- Antibody–Drug Conjugates (ADC)
- Bispecific Antibodies
- Next-generation Biologics
- Single-domain Antibodies (Nanobodies)
- Antibody Optimization